SOUTH SAN FRANCISCO, Calif., November 29, 2023 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International ALS/MND Symposium to be held in Basel, Switzerland and online from December 6, 2023 to December 8, 2023.
Oral presentations
Title: Site and participant perspectives on participating in an ALS trial designed to reduce burden: COURAGE-ALSPresenter: Stacy Rudnicki, MD, vice president, clinical research and therapeutic area lead, neuromuscular, cytokineticsDate: December 6, 2023Session title: Session 3B: Technology and telemedicineSession time: 3:15 p.m.-3:30 p.m. CETLocation: Singapore
Title: COURAGE-ALS: Results of the phase 3 clinical trial of Reldesemtiv in ALSPresenter: Jeremy M. Shefner, MD, Ph.D., professor of neurology, Barrow Neurological Institute, University of Arizona College of Medicine Phoenix Date: December 7, 2023Session title: Session 6B: Clinical trialsSession time: 10:30-10:50 CETLocation: Singapore
Poster presentations
Title: Analysis of plasma neurofilaments in VITALITY-ALS: analysis at baseline, longitudinal and by rate of disease progressionPresenter: Tyrell Simpkins, DO, Ph.D., Associate Medical Director, Neuromuscular Clinical Research, CytokineticsDate: December 6, 2023Session title: Theme 10 – Disease stratification and patient phenotyping Poster number: DSP-08Session time: 6:45 p.m. – 7:45 p.m. CETLocation: Halle Event
Title: Hospitalizations in COURAGE-ALS and their relationship with ALSPresenter: Stacy Rudnicki, MD, vice president, clinical research and therapeutic area lead, neuromuscular, cytokineticsDate: December 7, 2023Session title: Theme 09 – Clinical trials and trial design Poster number: CLT-20Session time: 5:45 p.m. – 6:45 p.m. CETLocation: Halle Event
Title: Investigating geographic differences in time from ALS symptom onset to key disease milestones: data from a real-world surveyPresenter: Paulos Gebrehiwet, Ph.D., MS, Manager, Health Economics and Outcomes Research, CytokineticsDate: December 7, 2023Session title: Theme 12 – Clinical care and supportPoster number:CMS-53Session time: 5:45 p.m. – 6:45 p.m. CETLocation: Halle Event
About cytokinetics
Cytokinetics is a late-stage specialty cardiovascular biopharmaceutical company focused on the discovery, development and commercialization of first-in-class muscle activators and next-generation muscle inhibitors as potential treatments for debilitating diseases in which performance of the heart muscle is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company develops small molecule drug candidates specifically designed to impact myocardial muscle function and contractility. Aficamten is a newborn cardiac myosin inhibitor, currently the subject of three phase 3 clinical trials: SEQUOIA-HCM, evaluating aficamten in patients with obstructive hypertrophic cardiomyopathy (HCM), MAPLE-HCM, evaluating aficamten monotherapy versus metoprolol monotherapy in patients with obstructive HCM and ACACIA-HCM, evaluating aficamten in patients with non-obstructive HCM. Cytokinetics also develops omecamtiv mecarbil, a heart muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-136, a cardiac troponin activator for the potential treatment of HFrEF and other types of heart failure, such as right ventricular failure, resulting from impaired cardiac contractility, and CK- 586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for potential treatment of HFpEF. In 2023, Cytokinetics celebrates 25 years of pioneering innovation in muscle biology and related pharmacology focused on diseases related to muscle dysfunction and muscle weakness conditions.
For more information on cytokinetics, visit www.cytokinetics.com and follow us X, LinkedIn, Facebook And Youtube.
Forward-looking statements
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intention or obligation to update these forward-looking statements and claims the safe harbor of the law for forward-looking statements. Examples of such statements include, but are not limited to, statements regarding the potential benefits of reldesemtiv, including its ability to provide a survival benefit to anyone with amyotrophic lateral sclerosis; The research and development activities of Cytokinetique and its partners; the timing of patient recruitment in the clinical trials of Cytokinetics and its partners; the design, timing, results, significance and utility of preclinical and clinical results; as well as the properties and potential benefits of Cytokinetics drug candidates. These statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, without limitation, potential difficulties or delays in the development, testing, regulatory approvals for the initiation of testing, advancement or sale of the product or the manufacturing or production of Cytokinetics’ drug candidates that could slow or prevent clinical development or approval of the product; recruiting patients or conducting clinical trials may be difficult or delayed; Cytokinetic drug candidates may have undesirable side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit the ability of Cytokinetics or its partners to conduct clinical trials; and Cytokinetics may not be able to obtain or maintain patent or trade secret protection for its intellectual property; Astellas’ decisions regarding the design, initiation, conduct, timing and continuation of development activities for reldesemtiv; standards of care could change, rendering Cytokinetic drug candidates obsolete; competing products or alternative therapies may be developed by others for the treatment of indications that Cytokinetics’ drug candidates and potential drug candidates may target; and risks and uncertainties related to the timing and receipt of payments from its partners, including milestones and royalties on potential future sales of products under Cytokinetics’ collaboration agreements with such partners. For more information about these and other risks relating to Cytokinetics’ business, investors should review Cytokinetics’ filings with the Securities and Exchange Commission.
CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the United States and certain other countries.
Contact: Cytokinetics Diane WeiserSenior Vice President, Corporate Communications and Investor Relations(415) 290-7757
Source: Cytokinetics, Incorporated
